Volume 21, Number 4—April 2015
Synopsis
Hantavirus Pulmonary Syndrome , Southern Chile, 1995–2012
Table 4
Study variables with significant differences between hantavirus pulmonary syndrome patients who did and did not survive, Hospital Puerto Montt, Puerto Montt, Chile, 1995–2012
| Variable | Survivors, no. (%), n = 56 | Nonsurvivors, no. (%), n = 24 | Odds ratio (95% CI) | p value |
|---|---|---|---|---|
| Systolic blood pressure <90 mm Hg* | 8 (14) | 10 (41.7) | 4.0 (1.3–12.1) | 0.014 |
| Respirations >30 breaths/min* | 13 (23) | 19 (79.2) | 15.3 (3.8–61.5) | 0.000 |
| Pulse >120 beats/min* | 14 (25) | 14 (58.3) | 4.0 (1.4–11.1) | 0.008 |
| Bleeding manifestations | 15 (27) | 17 (70.8) | 6.8 (2.3–19.7) | 0.000 |
| Creatinine >1.3 mg/dL* | 13 (23) | 13 (54.2) | 3.7 (1.2–10.6) | 0.017 |
| Admitted to intensive care unit | 39 (70) | 24 (100) | 0.001 | |
| Mechanical ventilation | 16 (29) | 24 (100) | 0.000 | |
| Shock | 13 (23) | 24 (100) | 0.000 | |
| Infiltrates in 4 quadrants in chest radiograph* | 21 (38) | 18 (75) | 5.0 (1.6–15.5) | 0.006 |
| PAFI <100* | 2 (4) | 5 (20.8) | 7.1 (1.2–41.2) | 0.008 |
| Classified as grade III (severe) | 17 (30) | 24 (100) | 0.000 |
*On admission. PAFI, arterial oxygen tension/inspiratory oxygen fraction.
Page created: March 17, 2015
Page updated: March 17, 2015
Page reviewed: March 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.